Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure.
The inhibitory effect of omeprazole on gastric acid secretion was tested in a group of patients on haemodialysis for chronic renal failure. Single 30 mg doses almost totally inhibited basal acid output on both dialysis and non-dialysis days. Plateau acid output was reduced by a mean of 77% and 90% on non-dialysis and dialysis days respectively. The absorption and pharmacokinetic profile of omeprazole were not affected by dialysis. Omeprazole was not recoverable from dialysis fluid. It is concluded that omeprazole is a potent inhibitor of gastric acid secretion in patients with chronic renal failure, and its effect is not influenced by haemodialysis.
D000328:Adult; D000897:Anti-Ulcer Agents / Q000378:metabolism* / Q000494:pharmacology; D001562:Benzimidazoles / Q000378:metabolism* / Q000494:pharmacology; D004381:Duodenal Ulcer / Q000209:etiology / Q000517:prevention & control; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009853:Omeprazole; D006435:Renal Dialysis
D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D009853:Omeprazole